Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1988 November; 82(5): 1574–1577.
PMCID: PMC442725

Potentiation of pentazocine analgesia by low-dose naloxone.


The analgesia produced by combinations of low-dose naloxone with pentazocine or morphine was studied in 105 patients with moderately severe postoperative pain after standardized surgery for removal of impacted third molars. Pain intensity was quantified using a visual-analogue scale. To eliminate the release of endogenous opioids produced by the placebo component of open drug administration, all injections were made by a preprogrammed infusion pump. The analgesia produced by pentazocine, an agonist-antagonist opiate-analgesic acting predominantly at the kappa opiate receptor, was potentiated by low-dose naloxone, whereas the analgesia produced by morphine, a mu-agonist, was attenuated by low-dose naloxone. To evaluate whether similar potentiation would be present in an animal model, and specifically, in the absence of diazepam, which patients receive, we performed an analogous experiment in rats in which nociceptive threshold was determined using the Randall-Selitto paw-withdrawal test. The results were completely analogous to the clinical results: pentazocine analgesia was potentiated by low-dose naloxone, whereas morphine analgesia was attenuated by low-dose naloxone. These data demonstrate a novel interaction between opiates, and suggest a rationale for opiate combinations to produce potent analgesia with fewer autonomic side effects and less abuse potential than presently available analgesics.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (783K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Le Bars D, Guilbaud G, Jurna I, Besson JM. Differential effects of morphine on responses of dorsal horn lamina V type cells elicited by A and C fibre stimulation in the spinal cat. Brain Res. 1976 Oct 22;115(3):518–524. [PubMed]
  • Frederickson RC, Burgis V, Edwards JD. Hyperalgesia induced by naloxone follows diurnal rhythm in responsivity to painful stimuli. Science. 1977 Nov 18;198(4318):756–758. [PubMed]
  • Levine JD, Gordon NC, Fields HL. Naloxone dose dependently produces analgesia and hyperalgesia in postoperative pain. Nature. 1979 Apr 19;278(5706):740–741. [PubMed]
  • Buchsbaum MS, Davis GC, Bunney WE., Jr Naloxone alters pain perception and somatosensory evoked potentials in normal subjects. Nature. 1977 Dec 15;270(5638):620–622. [PubMed]
  • Sewell RD, Spencer PS. Antinociceptive activitiy of narcotic agonist and partial agonist analgesics and other agents in the tail-immersion test in mice and rats. Neuropharmacology. 1976 Nov;15(11):683–688. [PubMed]
  • Woolf CJ. Analgesia and hyperalgesia produced in the rat by intrathecal naloxone. Brain Res. 1980 May 12;189(2):593–597. [PubMed]
  • Kayser V, Guilbaud G. Dose-dependent analgesic and hyperalgesic effects of systemic naloxone in arthritic rats. Brain Res. 1981 Dec 7;226(1-2):344–348. [PubMed]
  • Jasinski DR, Martin WR, Haertzen CA. The human pharmacology and abuse potential of N-allylnoroxymorphone (naloxone). J Pharmacol Exp Ther. 1967 Aug;157(2):420–426. [PubMed]
  • Jacob JJ, Ramabadran K. Enhancement of a nociceptive reaction by opioid antagonists in mice. Br J Pharmacol. 1978 Sep;64(1):91–98. [PMC free article] [PubMed]
  • Ward SJ, Takemori AE. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice. J Pharmacol Exp Ther. 1983 Mar;224(3):525–530. [PubMed]
  • Porreca F, Mosberg HI, Hurst R, Hruby VJ, Burks TF. Roles of mu, delta and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot-plate analgesia in the mouse. J Pharmacol Exp Ther. 1984 Aug;230(2):341–348. [PubMed]
  • Schmauss C, Yaksh TL. In vivo studies on spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther. 1984 Jan;228(1):1–12. [PubMed]
  • Yeung JC, Rudy TA. Multiplicative interaction between narcotic agonisms expressed at spinal and supraspinal sites of antinociceptive action as revealed by concurrent intrathecal and intracerebroventricular injections of morphine. J Pharmacol Exp Ther. 1980 Dec;215(3):633–642. [PubMed]
  • Levine JD, Lane SR, Gordon NC, Fields HL. A spinal opioid synapse mediates the interaction of spinal and brain stem sites in morphine analgesia. Brain Res. 1982 Mar 18;236(1):85–91. [PubMed]
  • Gilbert PE, Martin WR. The effects of morphine and nalorphine-like drugs in the nondependent, morphine-dependent and cyclazocine-dependent chronic spinal dog. J Pharmacol Exp Ther. 1976 Jul;198(1):66–82. [PubMed]
  • Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br J Pharmacol. 1980 Jul;69(3):503–512. [PMC free article] [PubMed]
  • Levine JD, Gordon NC. Influence of the method of drug administration on analgesic response. Nature. 1984 Dec 20;312(5996):755–756. [PubMed]
  • Levine JD, Taiwo YO, Collins SD, Tam JK. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primary afferent nociceptors. Nature. 1986 Sep 11;323(6084):158–160. [PubMed]
  • Levine JD, Lau W, Kwiat G, Goetzl EJ. Leukotriene B4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science. 1984 Aug 17;225(4663):743–745. [PubMed]
  • Beaver WT, Wallenstein SL, Houde RW, Rogers A. A comparison of the analgesic effects of pentazocine and morphine in patients with cancer. Clin Pharmacol Ther. 1966 Nov-Dec;7(6):740–751. [PubMed]
  • Goldstein G. Pentazocine. Drug Alcohol Depend. 1985 Feb;14(3-4):313–323. [PubMed]
  • Ngai SH, Berkowitz BA, Yang JC, Hempstead J, Spector S. Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action. Anesthesiology. 1976 May;44(5):398–401. [PubMed]
  • Bergman SA, Wynn RL, Myers DE, Rudo FG. Low dose naloxone enhances buprenorphine in a tooth pulp antinociceptive assay. Arch Int Pharmacodyn Ther. 1988 Jan-Feb;291:229–237. [PubMed]
  • Hazum E, Chang KJ, Leighton HJ, Lever OW, Jr, Cuatrecasas P. Increased biological activity of dimers of oxymorphone and enkephalin: possible role of receptor crosslinking. Biochem Biophys Res Commun. 1982 Jan 15;104(1):347–353. [PubMed]
  • Coy DH, Kastin AJ, Walker MJ, McGivern RF, Sandman CA. Increased analgesic activities of a fluorinated and a dimeric analogue of [D-Ala-2]-methionine enkephalinamide. Biochem Biophys Res Commun. 1978 Aug 14;83(3):977–983. [PubMed]
  • Rothman RB, Westfall TC. Allosteric coupling between morphine and enkephalin receptors in vitro. Mol Pharmacol. 1982 May;21(3):548–557. [PubMed]
  • Larson AA, Vaught JL, Takemori AE. The potentiation of spinal analgesia by leucine enkephalin. Eur J Pharmacol. 1980 Feb;61(4):381–383. [PubMed]
  • Lee NM, Leybin L, Chang JK, Loh HH. Opiate and peptide interaction: effect of enkephalins on morphine analgesia. Eur J Pharmacol. 1980 Nov 21;68(2):181–185. [PubMed]
  • Vaught JL, Rothman RB, Westfall TC. Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia. Life Sci. 1982 Apr 26;30(17):1443–1455. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation